FindTrial
Sign In

velaglucerase alfa

DRUG8 trials

Sponsors

Shire, Baylor Research Institute, Takeda

Conditions

Gaucher DiseaseGaucher Disease Type 1Gaucher Disease Type 3Gaucher Disease, Type 1Gaucher Disease, Type 3

Phase 1

Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease
CompletedNCT01685216
ShireGaucher Disease, Type 3
Start: 2012-09-14End: 2015-03-15Updated: 2021-06-11

Phase 3

Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
CompletedNCT00553631
ShireGaucher Disease, Type 1
Start: 2008-01-29End: 2009-05-05Updated: 2021-06-08
Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease
CompletedNCT01614574
ShireGaucher Disease
Start: 2012-03-02End: 2013-05-25Updated: 2021-06-28
Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease
CompletedNCT01842841
ShireGaucher Disease
Start: 2013-03-13End: 2014-10-08Updated: 2021-06-14
A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease
CompletedNCT05529992
TakedaGaucher Disease
Start: 2023-01-03End: 2024-08-05Updated: 2025-06-26

Phase 4

The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
WithdrawnNCT02528617
Baylor Research InstituteGaucher Disease Type 1, Gaucher Disease Type 3
Start: 2015-07-31End: 2017-10-31Updated: 2018-03-02
Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease
CompletedNCT02574286
ShireGaucher Disease
Start: 2016-06-29End: 2020-11-30Updated: 2022-02-01

Unknown Phase

Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
NCT00954460
ShireGaucher Disease, Type 1
Updated: 2021-05-21

Related Papers

Results From a 12-Month Open-Label Phase 1/2 Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease
Journal of Inborn Errors of Metabolism and Screening2018-01-014 citations
Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4 years in phase 3 trials
Blood Cells Molecules and Diseases2016-10-2129 citations
A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24 months
Blood Cells Molecules and Diseases2015-10-2211 citations
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long‐term data from phase III clinical trials
American Journal of Hematology2015-03-1951 citations
A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.
2013-11-2119 citations